[go: up one dir, main page]

PE20071057A1 - Derivados de sulfonamidoanilina como inhibidores de cinasas janus - Google Patents

Derivados de sulfonamidoanilina como inhibidores de cinasas janus

Info

Publication number
PE20071057A1
PE20071057A1 PE2006001667A PE2006001667A PE20071057A1 PE 20071057 A1 PE20071057 A1 PE 20071057A1 PE 2006001667 A PE2006001667 A PE 2006001667A PE 2006001667 A PE2006001667 A PE 2006001667A PE 20071057 A1 PE20071057 A1 PE 20071057A1
Authority
PE
Peru
Prior art keywords
sulfonamidoaniline
metansulphonamide
ilamino
purin
derivatives
Prior art date
Application number
PE2006001667A
Other languages
English (en)
Inventor
Hans-Georg Capraro
Bernard Coupez
Pascal Furet
Paul W Manley
Soldermann Carole Pissot
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20071057A1 publication Critical patent/PE20071057A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UN DERIVADO DE SULFONAMIDOANILINA DE FORMULA (I), DONDE A ES N O CH; W, X, Y Y Z SON CH; R1 ES NR4R5 U OR4; R4 ES ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS; R5 ES H, ALQUILO, ENTRE OTROS; R2 ES H, ALQUILO, ALQUENILO C1-C7; R3 ES ALQUILO, ALQUENILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[3-(6-CICLOBUTILAMINO-9H-PURIN-2-ILAMINO)-FENIL]-METANSULFONAMIDA, N-[3-(6-ISOPROPILAMINO-9H-PURIN-2-ILAMINO)-FENIL]-METANSULFONAMIDA, N-{3-[6-((S)-2-HIDROXIMETIL-PIRROLIDIN-1-IL)-9H-PURIN-2-ILAMINO]-FENIL}-METANSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE TIROSINA-CINASAS DE JANUS TALES COMO JAK-2 Y JAK-3 Y SON UTILES COMO AGENTES INMUNOSUPRESORES ASI COMO EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS
PE2006001667A 2005-12-22 2006-12-20 Derivados de sulfonamidoanilina como inhibidores de cinasas janus PE20071057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0526246.4A GB0526246D0 (en) 2005-12-22 2005-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
PE20071057A1 true PE20071057A1 (es) 2007-11-27

Family

ID=35841070

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001667A PE20071057A1 (es) 2005-12-22 2006-12-20 Derivados de sulfonamidoanilina como inhibidores de cinasas janus

Country Status (14)

Country Link
US (1) US20080261973A1 (es)
EP (1) EP1966210A2 (es)
JP (1) JP2009520725A (es)
KR (1) KR20080081177A (es)
CN (1) CN101331133A (es)
AR (1) AR058699A1 (es)
AU (1) AU2006328948B2 (es)
BR (1) BRPI0620449A2 (es)
CA (1) CA2631721A1 (es)
GB (1) GB0526246D0 (es)
PE (1) PE20071057A1 (es)
RU (1) RU2008129379A (es)
TW (1) TW200745113A (es)
WO (1) WO2007071393A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
US8404674B2 (en) 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
AU2008234822A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as JAK3 inhibitors
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
ES2546502T3 (es) 2008-04-16 2015-09-24 Portola Pharmaceuticals, Inc. 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
KR101098335B1 (ko) * 2008-07-18 2011-12-26 성균관대학교산학협력단 신코나 기재 이작용성 유기 촉매 및 이를 이용한 메소-고리산무수물의 비대칭 고리 열림 반응을 통한 키랄성헤미에스터의 제조방법
PL2331547T3 (pl) 2008-08-22 2015-01-30 Novartis Ag Związki pirolopirymidynowe jako inhibitory CDK
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
EP2405973B1 (en) * 2009-03-13 2015-04-22 Katholieke Universiteit Leuven, K.U. Leuven R&D Thiazolopyrimidine modulators as immunosuppressive agents
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011028864A1 (en) * 2009-09-03 2011-03-10 Bristol-Myers Squibb Company Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
JP2013523678A (ja) 2010-03-30 2013-06-17 ノバルティス アーゲー 慢性的に活性なｂ細胞受容体シグナル伝達を有するｂ細胞リンパ腫の治療用のｐｋｃ阻害薬
US8889684B2 (en) * 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
CA2856301C (en) 2011-11-23 2020-10-06 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
WO2013082476A1 (en) 2011-11-30 2013-06-06 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
EP2875013B1 (en) * 2012-07-17 2017-11-29 Glaxosmithkline Intellectual Property (No. 2) Limited Indolecarbonitriles as selective androgen receptor modulators
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
CN105008362B (zh) * 2013-02-22 2017-06-06 辉瑞大药厂 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
ES2761572T3 (es) 2013-07-11 2020-05-20 Acea Therapeutics Inc Derivados de pirimidina como inhibidores de quinasa
CN111285813A (zh) 2013-08-23 2020-06-16 润新生物公司 化学实体、组合物和方法
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
TW202204345A (zh) 2015-01-16 2022-02-01 美商通用醫院公司 改善mRNA剪接之化合物
CN107801397B (zh) 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
CN107613769A (zh) * 2015-02-17 2018-01-19 润新生物公司 某些化学实体、组合物和方法
JP6889494B2 (ja) 2015-10-09 2021-06-18 エイシア セラピューティクス， インコーポレイテッド ピロロピリミジンキナーゼ阻害剤の薬学的塩、物理的形態、および組成物、ならびにそれらを作製する方法
CA3033370A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3528816A4 (en) * 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
BR112019020840A2 (pt) 2017-04-07 2020-04-28 Acea Therapeutics Inc sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
US20220202820A1 (en) 2019-04-16 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
CN112010789A (zh) * 2019-05-31 2020-12-01 中国科学院上海药物研究所 乙烯基磺酰胺或乙烯基酰胺类化合物及其制备方法和用途
AU2022233254A1 (en) 2021-03-11 2023-10-26 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
JP2009511528A (ja) * 2005-10-13 2009-03-19 グラクソ グループ リミテッド Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群

Also Published As

Publication number Publication date
KR20080081177A (ko) 2008-09-08
EP1966210A2 (en) 2008-09-10
AR058699A1 (es) 2008-02-20
JP2009520725A (ja) 2009-05-28
WO2007071393A3 (en) 2007-07-26
BRPI0620449A2 (pt) 2011-11-08
WO2007071393A2 (en) 2007-06-28
US20080261973A1 (en) 2008-10-23
AU2006328948B2 (en) 2009-10-22
CA2631721A1 (en) 2007-06-28
RU2008129379A (ru) 2010-01-27
AU2006328948A1 (en) 2007-06-28
GB0526246D0 (en) 2006-02-01
CN101331133A (zh) 2008-12-24
TW200745113A (en) 2007-12-16

Similar Documents

Publication Publication Date Title
PE20071057A1 (es) Derivados de sulfonamidoanilina como inhibidores de cinasas janus
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
AP1822A (en) Substituted pyridinones as modulators of P38 MAP kinase.
TW200517109A (en) Substituted pyridinones
PE20091712A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
MXPA05010621A (es) Pirimidinonas sustituidas.
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
BRPI0514738A (pt) derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos
PE20060693A1 (es) Nuevos derivados de trifluorometansulfonanilida oxamida eter
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR063869A1 (es) Metodo de radiosensibilizacion de tumores usando un agente radiosensibilizante
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
PE20061067A1 (es) Derivados de pirimidina
PE20251706A1 (es) Compuestos de urea triciclica como inhibidores de v617f de jak2
ATE556712T1 (de) A2a antagonisten zur behandlung von motorischen störungen
PE20091079A1 (es) Compuestos heterociclicos como moduladores npy y2
DE602006018359D1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
SE0403118D0 (sv) New compounds 2
PE20060868A1 (es) Sales de aminio de 1,2,3- triazoles como profarmacos que incluyen agentes antivirales

Legal Events

Date Code Title Description
FD Application declared void or lapsed